Article Details

CatalYm Announces New Financing of $150M to Support Broad Phase 2b Development ...

Retrieved on: 2024-07-16 14:33:48

Tags for this article:

Click the tags to see associated articles and topics

CatalYm Announces New Financing of $150M to Support Broad Phase 2b Development .... View article details on hiswai:

Excerpt

Visugromab is a monoclonal antibody that neutralizes the tumor-derived Growth Differentiation Factor-15 (GDF-15), a locally acting immunosuppressant ...

Article found on: pipelinereview.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up